Biogen Inc./ US09062X1037 /
2024-04-26 7:57:14 AM | Chg. +2.3500 | Volume | Bid9:59:57 PM | Ask9:59:57 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
189.8000EUR | +1.25% | - Turnover: - |
195.0000Bid Size: 60 | 195.6000Ask Size: 60 | 30.42 bill.EUR | - | - |
GlobeNewswire
04-25
Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEM...
GlobeNewswire
04-23
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immu...
GlobeNewswire
03-13
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
GlobeNewswire
03-11
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...
GlobeNewswire
03-08
From the Beach to the Boardroom: Unispace's 'Art for Impact' Program Partners with NGO to Turn 50,00...
GlobeNewswire
03-07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BI...
GlobeNewswire
03-06
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-28
Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study
GlobeNewswire
02-27
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...